Multiple Myeloma Drug Pipeline Analysis Report 2025

Multiple myeloma is a type of blood cancer that affects plasma cells, a crucial component of the immune system. Globally, it ranks 24th among the most common cancers, accounting for approximately 1% of all cancer cases. Despite advancements, there remains a high unmet clinical need for more effective therapies, as current treatments such as proteasome inhibitors and immunomodulatory drugs often fail to provide long-term remission. The growing focus on targeted therapies, immune checkpoint inhibitors, and CAR-T cell therapies is expected to drive the development of promising multiple myeloma drug candidates. These innovations hold the potential to enhance treatment outcomes in the coming years.

Report Coverage

The Multiple Myeloma Drug Pipeline Insight Report by the publisher gives comprehensive insights into multiple myeloma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for multiple myeloma. The multiple myeloma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The multiple myeloma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with multiple myeloma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to multiple myeloma.

Multiple Myeloma Drug Pipeline Outlook

Multiple myeloma is a blood cancer that affects plasma cells, causing abnormal protein production, bone damage, and immune dysfunction. It arises from genetic mutations and bone marrow changes that drive uncontrolled cell growth. The multiple myeloma drug pipeline is expanding with immunotherapies, CAR-T cell therapies, bispecific antibodies, and next-generation proteasome inhibitors, aiming to improve treatment efficacy and patient survival.

Multiple myeloma treatment includes proteasome inhibitors, immunomodulators, monoclonal antibodies, and chemotherapy. Advancements include CAR-T cell therapies, bispecific T-cell engagers, and novel inhibitors. Stem cell transplantation remains vital for eligible patients. Emerging therapies focus on overcoming drug resistance and improving remission rates.

Multiple Myeloma Epidemiology

Multiple myeloma accounts for 1% to 1.8% of all cancer cases globally and is the second most common hematological malignancy. In 2025, the United States is expected to report 36,110 new cases. The United Kingdom records approximately 6,000 diagnoses and 3,000 deaths annually. In India, multiple myeloma incidence is rising, with higher rates in men at 1.13 per 100,000 compared to women at 0.81 per 100,000.

Multiple Myeloma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of multiple myeloma drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• CAR-T Cell Therapies
• Biologics

By Route of Administration

• Oral
• Parenteral
• Others

Multiple Myeloma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total multiple myeloma clinical trials.

Multiple Myeloma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the multiple myeloma pipeline analysis include small molecules, monoclonal antibodies, CAR-T cell therapies, and biologics. The multiple myeloma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for multiple myeloma.

Multiple Myeloma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the multiple myeloma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed multiple myeloma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in multiple myeloma clinical trials:

• Pfizer
• Amgen
• K36 Therapeutics, Inc.
• Celgene
• AbbVie
• Cullinan Therapeutics Inc.
• Sorrento Therapeutics, Inc.
• Juno Therapeutics, Inc.
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Genrix Biopharmaceutical Co., Ltd.
• AstraZeneca
• Cartesian Therapeutics
• Hoffmann-La Roche
• Novartis Pharmaceuticals

Multiple Myeloma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for multiple myeloma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of multiple myeloma drug candidates.

Drug: Elranatamab

The Elranatamab post-trial access study, sponsored by Pfizer, aims to evaluate the continued clinical benefit of Elranatamab monotherapy in multiple myeloma participants. This Phase 4 study is designed as an open-label, single-arm trial. It is expected to be completed by February 22, 2032, with approximately 80 participants enrolled.

Drug: BCD-264 and Darzalex

Biocad is sponsoring a Phase 3 study, DARVIVA, to examine the efficacy and safety of BCD-264 and Darzalex as monotherapy in patients with relapsed and refractory multiple myeloma. The objective is to compare the two drugs' profiles in subjects previously treated with proteasome inhibitors and immunomodulatory drugs. The study is expected to be completed by July 2026, enrolling around 252 participants.

Drug: GR1803 injection

Genrix (Shanghai) Biopharmaceutical Co., Ltd. is sponsoring a Phase II study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of GR1803 injection in patients with relapsed/refractory multiple myeloma. The study aims to assess treatment response and tolerability. The study is expected to be completed by August 1, 2027, with an estimated enrollment of 116 participants.

Reasons To Buy This Report

The Multiple Myeloma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for multiple myeloma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into multiple myeloma collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Multiple Myeloma - Pipeline Insight Report

• Which companies/institutions are leading the multiple myeloma drug development?
• What is the efficacy and safety profile of multiple myeloma pipeline drugs?
• Which company is leading the multiple myeloma pipeline development activities?
• What is the current multiple myeloma commercial assessment?
• What are the opportunities and challenges present in the multiple myeloma drug pipeline landscape?
• What is the efficacy and safety profile of multiple myeloma pipeline drugs?
• Which company is conducting major trials for multiple myeloma drugs?
• Which companies/institutions are involved in multiple myeloma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in multiple myeloma?

This product will be delivered within 3-5 business days.